Artivion Inc (AORT)vsAstraZeneca PLC (AZN)
AORT
Artivion Inc
$26.17
-2.71%
HEALTHCARE · Cap: $1.30B
AZN
AstraZeneca PLC
$155.62
+3.78%
HEALTHCARE · Cap: $263.09B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13279% more annual revenue ($61.37B vs $458.69M). AZN leads profitability with a 17.0% profit margin vs 2.5%. AZN appears more attractively valued with a PEG of 1.47. AZN earns a higher WallStSmart Score of 60/100 (C+).
AORT
Hold41
out of 100
Grade: D
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-32.5%
Fair Value
$30.26
Current Price
$26.17
$4.09 premium
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$155.62
$41.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 107.3x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AORT profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.25 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 41/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?